No products
View larger AOB11010
CAS: 2139288-26-7
Chemical Name: N-((R)-3-(4-(2-(3,5-Dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)-2-hydroxypropyl)methanesulfonamide
986 Items
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $420.75 | Total: $2,103.75 |
| 1 | 10 | $356.40 | Total: $3,564.00 |
| 1 | 25 | $301.95 | Total: $7,548.75 |
| 1 | 50 | $257.40 | Total: $12,870.00 |
| 1 | 100 | $222.75 | Total: $22,275.00 |
| Molecular Formula | C22H28Cl3NO6S |
| Molecular Weight | 540.88 |
| CAS Numbers | 2139288-26-7 |
| Storage Condition | 0°C (short term), -20°C (long term), desiccated |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| Synonym | EPI-7170; EPI 7170; EPI7170 |
| IUPAC/Chemical Name | N-((R)-3-(4-(2-(3,5-Dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)-2-hydroxypropyl)methanesulfonamide |
| InChl Key | DCXVYXPVNSMWPG-IAGOWNOFSA-N |
| InChl Code | InChI=1S/C22H28Cl3NO6S/c1-22(2,15-8-19(24)21(20(25)9-15)32-12-16(27)10-23)14-4-6-18(7-5-14)31-13-17(28)11-26-33(3,29)30/h4-9,16-17,26-28H,10-13H2,1-3H3/t16-,17-/m1/s1 |
| SMILES Code | CS(=O)(NC[C@@H](O)COC1=CC=C(C(C)(C2=CC(Cl)=C(OC[C@H](O)CCl)C(Cl)=C2)C)C=C1)=O |
| References | 1) Hirayama Y, Tam T, Jian K, Andersen RJ, Sadar MD. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer. Mol Oncol. 2020 Jul 30. doi: 10.1002/1878-0261.12770. Epub ahead of print. PMID: 32734688. 2) Banuelos CA, Ito Y, Obst JK, Mawji NR, Wang J, Hirayama Y, Leung JK, Tam T, Tien AH, Andersen RJ, Sadar MD. Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants. Cancers (Basel). 2020 Jul 21;12(7):E1991. doi: 10.3390/cancers12071991. PMID: 32708219. |
Potent androgen receptor N-terminal domain antagonist, decreasing expression of DNA repair genes, sensitizing prostate cancer cells that express full-length AR and AR-Vs to radiotherapy